Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 2, 1997, Pages 331-336

  Franzot, Sarah P ^a,b   Casadevall, Arturo ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Ullmann 1219 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; PNEUMOCANDIN DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FUNGAL MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL;

EID: 0031039601     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.2.331     Document Type: Article

References (18)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, D. Krupa, V. B. Pikounis, H. Kropp, and K. Bartizal. 1995. Evaluation of water-soluble pneumocandin analogs L-733,560, L-705,589, and L-731,373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 39:1077-1081.
2. Bartizal, K., T. Scott, G. K. Abruzzo, C. J. Hill, C. Pacholock, L. Lynch, and H. Kropp, 1995. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob. Agents Chemother. 39:1070-1076.
3. Brandt, M. E., L. C. Hutwagner, L. A. Klug, W. S. Baughman, D. Rimland, E. A. Graviss, R. J. Hamill, C. Thomas, P. G. Pappas, A. L. Reingold, R. W. Pinner, and the Cryptococcal Disease Active Surveillance Group. 1996. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. J. Clin. Microbiol. 34:912-917.
4. Currie, B. P., and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19:1029-1033.
5. de Lalla, F., G. Pellizzer, A. Vaglia, V. Manfrin, M. Franzetti, P. Fabris, and C. Stecca. 1994. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin. Infect. Dis. 20:263-266.
6. Dismukes, W. E. 1993. Management of cryptococcosis. Clin. Infect. Dis. 17(Suppl. 2):507-512.
7. Eliopoulos, G. M., and R. C. Moellering. 1991. Antimicrobial combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore.
8. Franzot, S. P., and J. S. Hamdan. 1994. Effect of amphotericin B on the lipids of five different strains of Cryptococcus neoformans. Mycopathologia 128:85-89.
9. Jahn, B., E. Martin, A. Stueben, and S. Bhakdi. 1995. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-dyphenyl-2H-tetrazolium bromide assay. J. Clin. Microbiol. 33:661-667.
10. Kwon-Chung, K. J., I. Polacheck, and J. E. Bennett. 1982. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J. Clin. Microbiol. 15:535-537.
11. Meshulam, T., S. M. Levitz, L. Christin, and R. D. Diamond. 1995. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanilide (XTT). J. Infect. Dis. 172:1153-1156.
12. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing for yeasts: proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. Nguyen, M. H., F. Barchiesi, D. A. McGough, V. L. Yu, and M. G. Rinaldi. 1995. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39:1691-1695.
14. Saag, M. S., and W. E. Dismukes. 1988. Azole antifungal agents: emphasis on new triazoles. Antimicrob. Agents Chemother. 32:1-8.
15. Spitzer, E. D., S. G. Spitzer, L. F. Freundlich, and A. Casadevall. 1993. Persistence of the initial infection in recurrent cryptococcal meningitis. Lancet 341:595-596.
16. Sugar, A. M., and C. Saunders. 1988. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am. J. Med. 85:481-489.
17. Tellier, R., M. Krajden, G. A. Grigoriew, and I. Campbell. 1992. Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob. Agents Chemother. 36:1619-1625.
18. Zuger, A., E. Louie, R. S. Holzman, M. S. Simberkoff, and J. J. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann. Intern. Med. 104:234-240.